Literature DB >> 6331877

Imbalances of T-cell subsets in monoclonal gammopathies.

L Bergmann, P S Mitrou, K C Weber, W Kelker.   

Abstract

In 42 patients with untreated or treated multiple myeloma (MM) or benign monoclonal gammopathy (BMG) the lymphocytes and T lymphocyte subsets were determined by monoclonal antibodies and other surface markers. In untreated MM, the T cells (1077/microliters vs 1439/microliters, P less than 0.01) and especially the OKT4+ lymphocytes (700/microliters vs 950/microliters, P less than 0.05) were significantly reduced compared with a control group. The OKT8+ cells were slightly but not significantly decreased. In previously treated MM, the loss of T cells was more pronounced than in the untreated group and was primarily caused by a further reduction of OKT4+ cells. Patients with BMG revealed decreased OKT8+ lymphocytes (304/microliters vs 502/microliters, P less than 0.001), whereas the OKT4+ cells were within the normal range. Therefore, the OKT4/OKT8 ratio was significantly elevated compared with that in untreated MM patients and normal controls (3.31 vs 2.06 vs 2.13; P less than 0.005). To sum up, in MM the results revealed a reduction of T cells, mainly of OKT4+ cells, which is intensified by chemotherapy and persists even after a long therapy-free interval. The different findings of T cell subsets in BMG and MM may be a helpful criterion to differentiate between BMG and MM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331877     DOI: 10.1007/bf00200046

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  SRBC rosette formation as a human T lymphocyte marker.

Authors:  M Jondal
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

2.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA.

Authors:  J L FAHEY; R SCOGGINS; J P UTZ; C F SZWED
Journal:  Am J Med       Date:  1963-11       Impact factor: 4.965

3.  Immunofluorescent method for positive identification of null-cell type acute lymphocytic leukemias: use of heterologous antiserum.

Authors:  M Kadin; R J Billing
Journal:  Blood       Date:  1977-11       Impact factor: 22.113

4.  Comparison in T- and B-cell markers in patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  C Morimoto; E L Reinherz; L M Nadler; J A Distaso; A D Steinberg; S F Schlossman
Journal:  Clin Immunol Immunopathol       Date:  1982-02

5.  E-rosette formation in B-cell lymphatic leukemias induced by binding activity of monoclonal surface immunoglobulins to sheep red blood cells.

Authors:  P S Mitrou; L Bergmann; K Holloway; G Zerth
Journal:  Clin Immunol Immunopathol       Date:  1981-09

6.  Further characterization of the human inducer T cell subset defined by monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  Subpopulations of T-lymphocytes in multiple myeloma.

Authors:  A Pezzutto; G Semenzato; C Agostini; R Raimondi; G Gasparotto
Journal:  Scand J Haematol       Date:  1981-04

8.  Expression of Ia-like antigen in lymphatic leukaemias and non-hodgkin lymphomas in correlation with other surface markers.

Authors:  L Bergmann; P S Mitrou; T Cherdron; K Holloway; J Jost; V Timm; G Zerth
Journal:  Scand J Haematol       Date:  1982-09

9.  In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma.

Authors:  D Peest; G Holm; H Mellstedt; D Pettersson
Journal:  Scand J Immunol       Date:  1982-06       Impact factor: 3.487

10.  Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes.

Authors:  R S Krakauer; W Strober; T A Waldmann
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

View more
  6 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Sex hormones and immune dysregulation in multiple myeloma.

Authors:  H Everaus; J Lehtmaa
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseases.

Authors:  G De Rossi; G De Sanctis; V Bottari; M Tribalto; M Lopez; M T Petrucci; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

5.  Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients.

Authors:  H M Serra; M J Mant; B A Ruether; J A Ledbetter; L M Pilarski
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.